BridgeMD
Prevention study for Nasopharyngeal Cancinoma (NPC)
Official title Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
ClinicalTrials.gov ID: NCT07311772
What this study is testing
What is Houyanqing Oral Liquid?
Houyanqing Oral Liquid is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for nasopharyngeal cancinoma (npc).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- To explore the efficacy of Houyanqing Oral Liquid combined with conventional treatment in preventing and treating radiation-induced oral mucositis, so as to improve the quality of life of nasopharyngeal carcinoma patients received radiotherapy.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer...
- Age: 18 to 75 years old;
- Karnofsky Performance Status (KPS) score ≥ 80 before treatment;
- No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy;
- Requiring radical radiotherapy;
You likely can't join if
- Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments;
- Previous history of head and neck radiotherapy;
- Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs);
- Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or...
- Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic/local use of corticosteroids at immunosuppressive doses before...
- HIV-positive patients;
See the full eligibility criteria
- Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC);
- Age: 18 to 75 years old;
- Karnofsky Performance Status (KPS) score ≥ 80 before treatment;
- No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy;
- Requiring radical radiotherapy;
- The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures.
- Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments;
- Previous history of head and neck radiotherapy;
- Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs);
- Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) mouthwash in the oral cavity...
- Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic/local use of corticosteroids at immunosuppressive doses before enrollment;
- HIV-positive patients;
- Pregnant women or lactating women;
- Patients with severe mental illnesses;
- Patients with severe cardio-cerebrovascular diseases, endocrine disorders, infectious diseases, or other tumors.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
- Fuzhou, Fujian, China
- Guangzhou, Guangdong, China
- Shantou, Guangdong, China
- Zhuhai, Guangdong, China
- Nanning, Guangxi, China
- Wuzhou, Guangxi, China
- Changsha, Hunan, China
- Changzhou, Jiangsu, China
- Shanghai, Shanghai Municipality, China
- Chengdu, Sichuan, China
- Kunming, Yunnan, China
- Hangzhou, Zhengjiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China; Fuzhou, Fujian, China; Guangzhou, Guangdong, China; Shantou, Guangdong, China; Zhuhai, Guangdong, China; Nanning, Guangxi, China and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.